Teva Pharmaceuticals USA, Inc.
$67.4M 141,158 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Advanced Accelerator Applications
Advanced Accelerator Applications reported $63,931,988.05 across General Payments, Research, and Ownership to 167 physicians and teaching hospitals across 167 transactions.
- $63.9M
- All-tracks total
- 167
- Transactions
- 167
- Recipients
- +$56.0M
- General Payments vs PY2023
Advanced Accelerator Applications reported $63,931,988.05 across all CMS Open Payments tracks (General + Research + Ownership) to 167 physicians and teaching hospitals in Program Year 2024 - ranking #41 of 1,925 reporting manufacturers (0.5% of the all-tracks industry total); General Payments alone were $63,931,988.05, averaging $382.8K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer advanced-accelerator-applications Advanced Accelerator Applications
$63.9M · #41/1,925 · 0.5% industry · PY2024
- TOT $63.9M
- RANK #41
- SHARE 0.5%
- TXN 167
- RCP 167
- CAT 1
- GEN $63.9M
- ΔGEN +$56.0M
- TOP1 100.0%
- PY 2024
Volume peers
Nearest volume peer: Teva Pharmaceuticals USA, Inc. ($67.4M)
Advanced Accelerator Applications sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Advanced Accelerator Applications's CMS-reported General Payments increased by $56.0M (+706.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ADVANCED ACCELERATOR APPLICATIONSPY2023: ADVANCED ACCELERATOR APPLICATIONSPY2024: Advanced Accelerator Applications. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $7,925,439.93
- PY2024
- $63,931,988.05
What the Data Shows for Advanced Accelerator Applications
Advanced Accelerator Applications ranks #41 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, representing 0.5% of all industry payments reported nationwide for the year. The underlying total is $63,931,988.05 across 167 transactions to 167 physicians and teaching hospitals - $382.8K per transaction and $382.8K per recipient on average.
Of the 1 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $63.9M across 167 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 1 types of general payments, Advanced Accelerator Applications's largest category was "Compensation for Services Other Than Consulting" at $63.9M - 100.0% of General Payments.
How Advanced Accelerator Applications divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $63.9M | 167 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $63,931,988.05 (100.0%) of $63,931,988.05 in this company's General Payments records across 1 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Advanced Accelerator Applications
The five named recipients with the highest reported General Payments from this company
- 1
Univ Of Missouri Health Care
$63,931,988.05 across 167 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Advanced Accelerator Applications's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Advanced Accelerator Applications.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Advanced Accelerator Applications.
Showing 6 of 1,924 companies with CMS-reported payment data.
Biogen, Inc.
$59.9M 36,001 recipients
Compare payment profiles
Bayer Healthcare Pharmaceuticals Inc.
$58.0M 146,928 recipients
Compare payment profiles
Gilead Sciences, Inc.
$72.7M 118,932 recipients
Compare payment profiles
Lilly USA, LLC
$54.3M 544,473 recipients
Compare payment profiles
Intuitive Surgical, Inc.
$74.7M 126,596 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.